Tecan Group (TECN) H2 2025 TU earnings summary

Executive summary

• Returned to sales growth in the second half of 2025, with strong order entry momentum in local currencies.

• Full-year sales in local currencies aligned with the previously confirmed outlook.

• Focus remains on performance enhancement, profitability improvement, and leveraging AI adoption in life sciences.

Financial highlights

• Group sales for 2025 totaled CHF 882.5 million, down 1.6% in local currencies and 5.5% in Swiss francs year-over-year.

• Second-half sales grew 0.4% in local currencies, with CHF 443.0 million in sales.

• Order entry reached CHF 900.9 million, up 3.8% in local currencies for the year and 8.6% in the second half.

• Book-to-bill ratio remained above 1 in both business segments.

Outlook and guidance

• Adjusted EBITDA margin guidance for 2025 reaffirmed.

• Medium-term outlook anticipates a return to mid- to high-single-digit organic growth rates in local currencies under normal market conditions.

• End markets expected to recover gradually in 2026, with no full normalization anticipated.

• 2026 guidance to be provided with full audited results in March 2026.